Etravirine, an FDA-approved non-nucleoside reverse transcriptase inhibitor for HIV, is being repositioned for the treatment of Friedreich Ataxia (FA), a rare neurodegenerative disorder with no current approved therapies. The trial aims to assess its safety and efficacy in a small cohort of FA patients, potentially opening a new therapeutic avenue in a niche market. Given the favorable safety profile of Etravirine and the unmet medical need in FA, successful outcomes could lead to significant market opportunities, particularly in rare disease segments. The competitive landscape remains limited due to the rarity of FA, but diligence should focus on ongoing and future studies targeting Frataxin and related pathways.